Dysregulation of the HER2/neu (ERBB2) receptor tyrosine kinase is another noteworthy molecular aberration in serous EC considering that HER2 is a proven druggable molecular target in other cancers, such as breast [24] or gastric cancer [25]. The gene discussed is ERBB2; the disease is cancer.